Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$13.01 -2.4%	$12.40	$8.04 ▼ $25.88	$361.52M	2.3	425,357 shs	656,158 shs
CNST Constellation Pharmaceuticals	$33.99	$33.89	$17.00 ▼ $39.30	$1.63B	2.59	940,325 shs	N/A
MNKD MannKind	$3.74 -0.5%	$4.32	$3.63 ▼ $7.63	$1.14B	1.02	2.42 million shs	3.32 million shs
RYTM Rhythm Pharmaceuticals	$63.19 +0.7%	$62.50	$40.46 ▼ $69.89	$3.99B	2.3	552,218 shs	785,290 shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+8.46%	+5.54%	+25.87%	-45.26%
CNST Constellation Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MNKD MannKind	0.00%	-0.27%	-9.62%	-25.25%	-27.97%
RYTM Rhythm Pharmaceuticals	0.00%	+1.19%	+2.23%	+18.43%	+52.78%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	3.6009 of 5 stars	4.6	2.0	0.0	0.0	2.7	2.5	0.6
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	3.0381 of 5 stars	3.6	1.0	0.0	0.0	2.6	1.7	1.9
RYTM Rhythm Pharmaceuticals	3.8739 of 5 stars	3.5	2.0	0.0	4.3	1.9	0.8	0.6
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	311.22% Upside
CNST Constellation Pharmaceuticals	0.00	N/A	N/A	N/A
MNKD MannKind	3.29	Buy	$10.33	176.29% Upside
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	22.34% Upside
TRIL Trillium Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RYTM, ARCT, TRIL, CNST, and MNKD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
4/10/2025	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
4/10/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$12.00
4/9/2025	MNKD MannKind	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/8/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$152.31M	2.32	N/A	N/A	$8.90 per share	1.46
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	$8.63 per share	N/A
MNKD MannKind	$285.50M	3.98	$0.14 per share	27.09	($0.29) per share	-12.90
RYTM Rhythm Pharmaceuticals	$130.13M	30.89	N/A	N/A	$0.35 per share	180.54
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/4/2025 (Estimated)
CNST Constellation Pharmaceuticals	-$126.36M	-$2.81	N/A	N/A	N/A	N/A	-33.12%	-29.92%	N/A
MNKD MannKind	$27.59M	$0.10	37.40	16.26	N/A	10.12%	-32.41%	10.85%	8/6/2025 (Estimated)
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest RYTM, ARCT, TRIL, CNST, and MNKD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	MNKD MannKind	$0.03	$0.04	+$0.01	$0.04	$75.86 million	$78.35 million
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CNST Constellation Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	0.06	5.64	5.64
CNST Constellation Pharmaceuticals	N/A	15.39	15.39
MNKD MannKind	N/A	2.36	2.11
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
TRIL Trillium Therapeutics	N/A	19.82	19.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CNST Constellation Pharmaceuticals	N/A
MNKD MannKind	49.55%
RYTM Rhythm Pharmaceuticals	N/A
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	15.30%
CNST Constellation Pharmaceuticals	43.70%
MNKD MannKind	3.00%
RYTM Rhythm Pharmaceuticals	6.10%
TRIL Trillium Therapeutics	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.97 million	Optionable
CNST Constellation Pharmaceuticals	154	47.92 million	N/A	Not Optionable
MNKD MannKind	400	303.93 million	294.82 million	Optionable
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

RYTM, ARCT, TRIL, CNST, and MNKD Headlines

Recent News About These Companies

Ratio Therapeutics and TerraPower Isotopes Sign Supply Agreement for Actinium-225 For Targeted Radiotherapeutics

June 20, 2025 | finance.yahoo.com

Trillium Therapeutics Stock Price History

May 26, 2025 | investing.com

TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal

September 26, 2024 | ipwatchdog.comI

Advances in Drug Discovery & Development 2024

September 8, 2024 | technologynetworks.comT

When You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) Stock

July 30, 2024 | finance.yahoo.com

Google Cloud unveils the Trillium TPU, its most powerful AI processor so far

May 14, 2024 | siliconangle.comS

Cachet Bicycle shakes off COVID

February 25, 2024 | baytoday.caB

Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics

January 30, 2024 | chch.comC

TTI apprehends motorists for illegal removal of clamps, hunt for four others underway

January 30, 2024 | bulawayo24.comB

BridgeBio raises $1.25bn, and other biotech financings

January 19, 2024 | pharmaphorum.comP

Ratio Therapeutics Raises $50M in Series B Financing

January 17, 2024 | precisionmedicineonline.comP

Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com

November 10, 2023 | businesswire.com

Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions

November 8, 2023 | benzinga.com

The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period

July 31, 2023 | uk.finance.yahoo.com

Ratio Therapeutics unveils new research and development facility

May 15, 2023 | biopharma-reporter.comB

WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'

April 25, 2023 | msn.com

Leukemia Therapeutics Global Market Report 2023

April 4, 2023 | uk.finance.yahoo.com

Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck

March 28, 2023 | finance.yahoo.com

Trillium House, an affordable housing project in Warrenton, close to completion

January 9, 2023 | dailyastorian.comD

FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma

October 19, 2022 | nz.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM, ARCT, TRIL, CNST, and MNKD Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$13.01 -0.32 (-2.40%)

As of 04:00 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Constellation Pharmaceuticals NASDAQ:CNST

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

MannKind NASDAQ:MNKD

$3.74 -0.02 (-0.53%)

As of 04:00 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Rhythm Pharmaceuticals NASDAQ:RYTM

$63.19 +0.46 (+0.73%)

As of 04:00 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time